Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
2
Interventional Options for TRD: ECT, TMS, and Esketamine
3
Sexual Dysfunction in Depression: Assessing Pleasure Alongside Desire, Arousal, and Orgasm
4
When PHQ-9 Scores Mislead: Rating Scales and Clinical Judgment
5